Dr Reddy's launches generic Ozempic in India, slashes prices by 50%
Big news for diabetes care—Dr. Reddy's plans to launch a generic version of Ozempic in India on March 21, 2026, making this popular weekly injection way more affordable.
With Novo Nordisk's patent set to expire on March 21, 2026, the price per pen could be about ₹3,600, potentially less than half the current price.
That could be a 50-60% cut, which could be a real game-changer for people with Type-2 diabetes.
What's inside and how it's made
This new generic Ozempic is an injectable semaglutide and comes in easy-to-use pens. Dr. Reddy's aims to produce 12 million units in the first year and even makes the key ingredient themselves.
They've teamed up with Indian companies to get these pens out to more people.
More on the way—and some competition too
Dr. Reddy's isn't stopping here—they're working on oral semaglutide (a pill version) and even a Wegovy alternative for obesity treatment down the line, aiming for over 80 countries including Canada and Brazil.
But they aren't alone; other manufacturers are also preparing to enter the market ahead of patent expiry, which should help push prices down further and get these meds to more people who need them.